Abstract
Platelet-Rich Plasma (PRP), a core biotherapeutic material in regenerative medicine, exhibits unique advantages in wound healing and tissue regeneration owing to its high concentrations of platelets and diverse bioactive factors, including albumin, fibrinogen, globulins, and growth factors such as Transforming growth factor-β1 (TGF-β1), Platelet-derived growth factor (PDGF), and Vascular endothelial growth factor (VEGF) [1]. However, the paradoxical bidirectional regulatory effects observed in its clinical application have garnered increasing attention: while PRP accelerates wound healing by promoting cell proliferation, angiogenesis, and ordered collagen deposition, it may also induce hypertrophic scars or even keloids due to excessive fibroblast activation and dysregulated extracellular matrix (ECM) metabolism [2,3]. This bidirectional effect underscores an urgent unmet clinical need: the lack of mechanistic understanding of PRP's scar-modulating pathways has prevented the development of precision strategies to maximize its therapeutic potential while mitigating fibrotic risks. Current research remains limited to broad biochemical signaling or generic ECM remodeling [4,5], with no focus on the mechanotransduction networks that bridge PRP's biological and physical effects on scar tissue.Recent advances in mechanotransduction research have shown that cellular sensing and response to matrix mechanical cues (e.g., stiffness, tension) are critical regulators of ECM metabolism and scar fate. Among these, Piezo1-the first identified mechanosensitive cation channel in eukaryotes (non-selective, permeable to Na⁺, Ca²⁺, and other ions) [6,7]-is overexpressed in scar tissue, responds to mechanical stretch, and drives fibroblast activation and hypertrophic scar formation [8,9]. The interplay between its activation and YAP/TAZ nuclear translocation serves as the central mechanism by which mechanical and certain chemical signals influence scar outcomes [10][11][12]. In skin fibrosis, Piezo1 forms a positive feedback loop by sensing tissue stiffness: its upregulation promotes a fibroblast proliferative phenotype, whereas Piezo1-knockout fibroblasts lose their fibrotic traits even on high-stiffness substrates [13,14]. Piezo1-YAP/TAZ is consistently implicated in scar pathogenesis: Piezo1 is overexpressed in hypertrophic scar/keloid fibroblasts and YAP/TAZ nuclear translocation directly promotes fibroblast activation and ECM deposition [8,9,12]. No other pathway has been shown to integrate PRP's dual biochemical-mechanical actions, making it the most relevant and translatable target for optimizing PRP therapy. Beyond skin, Piezo1 has been implicated in pulmonary fibrosis [15], cardiac fibrosis [16], and liver fibrosis [17], suggesting its broader role in mechanotransduction-driven fibrotic diseases. However, its mechanistic contribution may vary across organs and contexts.Previous studies have suggested that PRP may activate or synergize with the Piezo1 channel via its abundant growth factors and potential lipid components, concurrently triggering critical Ca²⁺ signaling cascades that drive angiogenesis, cell proliferation, differentiation, and matrix remodeling-ultimately promoting the regeneration of damaged myocardial tissue [18]. Regarding whether PRP can directly activate the Piezo1 channel, current evidence lacks direct experimental validation; however, indirect correlations and theoretical support have been proposed: the platelet plasma membrane in PRP may supply phosphatidylinositol bisphosphate (PIP₂), a lipid molecule recognized as a co-factor for Piezo1 channel activation [18][19][20][21].Despite the well-established pro-regenerative effects of PRP, a critical knowledge gap persists in understanding whether PRP modulates fibroblast behavior and scar progression through the Piezo1-mediated mechanotransduction pathway. Based on our understanding of PRP's active components, Piezo1's functional roles (mechanosensing and pro-fibrotic activity), and their established regulatory crosstalk, we propose the following plausible hypothesis: PRP bidirectionally regulates scar formation by activating the Piezo1 channel on fibroblast surfaces, thereby modulating fibroblast proliferation, differentiation, and ECM metabolism. This framework not only clarifies PRP's molecular mechanism of action but also provides a targeted strategy to optimize clinical outcomes (e.g., Piezo1 inhibitors, injection parameter tuning), filling the unmet need for precision anti-scar therapies.We propose that PRP bidirectionally modulates fibroblast function and scar progression by targeting the Piezo1-YAP/TAZ mechanotransduction axis via multidimensional biological effects (Figure 1.). During physiological repair, this modulation attenuates scar formation; during pathological fibrosis, it promotes the development of hypertrophic scars or keloids. We further hypothesize that PRP regulates the Piezo1 channel through the following mechanisms:2.1 TGF-β1 secreted by PRP upregulates Piezo1 expression/activity, and the two interact via positive/negative feedback loops to modulate scar formation [22][23][24][25].2.2 PRP alters tissue mechanical properties (e.g., stiffness) by inducing cell proliferation and matrix remodeling. Changes in the stiffness of its contained fibrin matrix further tune the tension of the tissue mechanical microenvironment, thereby regulating Piezo1 channel activity.The platelet plasma membrane in PRP may supply phosphatidylinositol bisphosphate (PIP₂)-a lipid molecule known to activate the Piezo1 channel [18][19][20][21].During PRP injection therapy, mechanical force from the injection directly activates the Piezo1 channel. PRP injection may also activate mechanosensitive Piezo1 channels by locally increasing tissue tension.The core pathological process of hypertrophic scarring (e.g., in skin wounds and visceral organs like the lung or liver) involves...

This publication has 69 references indexed in Scilit: